key: cord-1018213-i0afxpj1
authors: Esmail, Sally; Danter, Wayne R.
title: Viral pandemic preparedness: A pluripotent stem cell‐based machine‐learning platform for simulating SARS‐CoV‐2 infection to enable drug discovery and repurposing
date: 2020-09-22
journal: Stem Cells Transl Med
DOI: 10.1002/sctm.20-0181
sha: be37f9bd3aac743adf3377c747cb184167eddaf7
doc_id: 1018213
cord_uid: i0afxpj1

Infection with the SARS‐CoV‐2 virus has rapidly become a global pandemic for which we were not prepared. Several clinical trials using previously approved drugs and drug combinations are urgently underway to improve our current situation. Unfortunately, a vaccine option is optimistically at least a year away. It is imperative that for future viral pandemic preparedness, we have a rapid screening technology for drug discovery and repurposing. The primary purpose of this research project was to evaluate the DeepNEU stem‐cell based platform by creating and validating computer simulations of artificial lung cells infected with SARS‐CoV‐2 to enable the rapid identification of antiviral therapeutic targets and drug repurposing. The data generated from this project indicate that (a) human alveolar type lung cells can be simulated by DeepNEU (v5.0), (b) these simulated cells can then be infected with simulated SARS‐CoV‐2 virus, (c) the unsupervised learning system performed well in all simulations based on available published wet lab data, and (d) the platform identified potentially effective anti‐SARS‐CoV2 combinations of known drugs for urgent clinical study. The data also suggest that DeepNEU can identify potential therapeutic targets for expedited vaccine development. We conclude that based on published data plus current DeepNEU results, continued development of the DeepNEU platform will improve our preparedness for and response to future viral outbreaks. This can be achieved through rapid identification of potential therapeutic options for clinical testing as soon as the viral genome has been confirmed.

Infection with the SARS-CoV-2 virus and the resultant COVID-19 disease has rapidly become the most lethal global pandemic when compared to the SARS and H1N1 outbreaks in 2003 and 2009, respectively. 1 SARS-CoV-2 is essentially a new virus to the human host, although it shares >80% genetic homology with the SARS-CoV-2 virus responsible for the 2003 outbreak. 1 As a result, we as a population have little or no innate immunity to this new pathogen.

We also have essentially no effective treatment for SARS-CoV-2 infection or vaccine to prevent infection. A few brave physicians have made the decision to treat SARS-CoV-2 infected patients with off label approved drugs with encouraging but preliminary results. Many clinical trials with previously approved drugs and drug combinations are currently underway to improve this therapeutic dilemma. Unfortunately, a vaccine option for the general public is optimistically at least a year away.

In the last two decades, our world has experienced outbreaks of Ebola, SARS, H1N1, and now SARS-CoV-2. As the World Health Organization (WHO) has clearly stated, new and lethal viral pathogens are certain to emerge in the future and if we disregard this warning, we are likely to experience similar pandemics in the future. It is imperative that we are prepared to act as early as possible when or ideally before future viral outbreaks.

The advent of reprogramming human induced pluripotent stem cells (iPSCs) from donors' somatic cells has created new opportunities to study and understand the underlying pathophysiology of human diseases, including a growing number of viral infections, like Zika Virus (ZIKV), hepatitis C virus (HCV), and Influenza virus (H1N1). 2, 3 Unfortunately, cellular reprogramming to produce iPSCs remains a challenge due to the high costs, demanding resource needs and the tendency of iPSCs to revert to their original somatic genotypes over time. Importantly, the limited access to donor cells also remains a major concern especially for developing new drug therapies for viral and other infectious diseases. To overcome the technological and ethical limitations still associated with iPSC models, we have created DeepNEU. The DeepNEU platform is a validated hybrid deep-machine learning system with elements of fully connected recurrent neural networks (RNNs), cognitive maps (CMs), support vector machines, and evolutionary systems (GA). Previously the DeepNEU platform has been used to generate artificially induced pluripotent stem cells (aiPSCs), neural stem cells, cardiomyocytes, and skeletal muscle cells. 4, 5 The purpose of the present research was to evaluate an updated version of our machine-learning platform DeepNEU v5.0 for creating computer simulations of artificially induced type 1 (AT1) and type 2 (AT2) alveolar lung cells (aiLUNG) derived from artificially induced human pluripotent stem cells (aiPSCs). These uninfected aiLUNG cells were then exposed to infection with simulated SARS-CoV-2 virus (aiLUNG-COVID19). Finally, the aiLUNG-COVID19 simulations were applied to drug repurposing of a small group of approved drugs with well-known mechanisms of action. The genomic and phenotypic profiles of uninfected wild-type aiLUNG (aiLUNG-WT) cells and aiLUNG-COVID19 simulations were validated based on the currently available experimental wet lab and other data. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Ideally, in the future, this new technology would be implemented as soon as the new viral genome has been identified and validated. For example, the SARS-CoV-2 genome and cell receptor data were published in early March 2020 (GenBank accession number: MT126808.1).

The DeepNEU platform is a literature validated hybrid deep-machine learning system with elements of fully connected RNNs, CMs, and evolutionary systems (GA). 4, 5 The detailed methodology for simulation development and validation used in the current experiments has been described previously. 4, 5 The current DeepNEU database (v5.0) contains all the information found in the previous version (v3.6) plus important information upgrades in the form of new gene, protein, and phenotypic relationship data. For example, the previous DeepNEU database version (3.6) contained 3187 gene/proteins or phenotypic concepts and 31 027 nonzero relationships while the current version (5.0) contains 4206 gene/proteins or phenotypic concepts and 37 223 nonzero relationships. This represents more than 1200 new relationships specifically relevant to the SARS-CoV-2 viral genome.

Each gene/protein and phenotypic concept in DeepNEU v5.0 has on average 9 gene/protein or phenotypic inputs and outputs.

The initial goal of this project was to create computer simulations (aiPSCs) of human induced pluripotent stem cells (iPSC) and artificially induced lung (aiLUNG) cell models then validate these models using the results published by References 4, 5, 7, 12, 13, 15, 20, 22 , and 23 and others as described above. Briefly, for the aiPSC models, the input

The current results showed that validated DeepNEU v5.0 platform of this study accurately derived artificially induced lung cells (aiLUNG) cells from artificially induced pluripotent stem cells (aiPSC) simulations. The aiLUNG simulations could be exposed to simulated SARS-CoV-2 virus and reproduce the genotypic and phenotypic profile associated with the infection. This study also demonstrated that the aiLUNG-COVID-19 simulations can be used to rapidly repurpose novel and known drug combinations with anti-SARS-CoV-2 therapeutic potential for animal and human trials validation. The rational process described in this article required the existence of a validated genome for the viral genome(s) in question. While DeepNEU requires continued development and validation, it is very likely that the most important application of this technology will be in improving disease preparedness for future outbreaks.

or initial state vector of dimension N was set to all zeros except for transcription factors OCT4, KLF4, SOX2, and cMYC (also known as OKSM). These four factors were given a value of +1 indicating that they were turned on for the first iteration. These values were not locked on so that after the first iteration all values were determined by evolving system behavior. The simulated lung cell models (aiLUNG) were created through direct conversion of the aiPSCs to aiLUNG cells using overexpression of NK2 Homeobox 1 (NKX-2.1), and Wnt Family Member 5A (Wnt5a) in the presence of a simulated lung cell medium. 12, 20 Once validated with published peer reviewed data, the aiLUNG simulations were exposed to simulated SARS-CoV-2 infection by turning on extracellular Spike-RBD (Receptor Binding Domain) in the presence of active Transmembrane Serine Protease 2 (TMPRSS2). Finally, several potential factors and combinations of factor inhibitors were evaluated regarding their ability to reduce the production and release of new SARS-CoV-2 viral particles. A summary of the 12 key simulations generated in the present study are presented in Table 1 Statistical analysis of the aiPSC and aiLUNG predictions vs the published data used the unbiased binomial test. This test provides an exact probability, can compensate for prediction bias, and is ideal for determining the statistical significance of experimental deviations from an actual distribution of observations that fall into two outcome categories (eg, agree vs disagree). A P value <.05 is considered significant and is interpreted to indicate that the observed relationship between aiPSC predictions and actual outcomes is unlikely to have occurred by chance alone. 

In this study, we began by programming DeepNEU (v5.0) to simulate iPSCs (i.e, aiPSCs) using a defined set of reprogramming factors 4,5 in the presence of ascorbic acid and doxycycline. Following the protocol (OKSM) were turned on as were ascorbic acid and doxycycline. 4, 5 The unsupervised aiPSC model converged quickly (20 iterations alkaline phosphatase (ALP), and NANOG protein. 24 Importantly, all the undifferentiated ESC/iPSC makers mentioned above regarding iPSC were also upregulated/expressed in the aiPSC simulations. The probability that all (N = 15) of these aiPSC-WT outcomes were correctly predicted by chance alone using the binomial test is .0021.

These results are presented in Figures S1 and S2.

Once validated the aiPSC simulations were used to create the wildtype lung cell simulations (aiLUNG) by activating NKX2.1 and Wnt5a

in the presence of a simulated lung cell medium as described previously. 12, 20 The unsupervised aiLUNG simulations converged quickly The aiLUNG simulations produced a similar expression profile when compared with actual human wild-type lung cell specific factors outlined above ( Figure 1A) , consistent with previous studies. 4, 5, 7, 12, 13, 15, 20, 22, 23 The probability that all (N = 15) of these aiLUNG outcomes were correctly predicted by chance alone using the binomial test is .0021. Importantly, the data also indicate that the generation of aiLUNG cells from aiPSC produces a heterogenous population of alveolar cell precursors and more mature alveolar cells ( Figure 1B ), consistent with previous study. 25 

Once validated against current published wet lab data, the aiLUNG cells were exposed to simulated SARS-CoV-2 virus. pig farmers became ill with encephalitis) has been associated with a human death rate of 70% 30 compared with the 1% to 2% death rate seen so far with COVID-19 infection. It would make remarkable good sense to begin planning for the next outbreak now.

In addition to disease modeling, DeepNEU has also been designed to be used as a tool for rapid and cost-effective therapeutic target identification and drug discovery. The use of stem cells for targeted drug discovery has been well reported in the peer-reviewed literature. [31] [32] [33] Our previously published approach to this issue has three simple components. 5 Although we were focused on repurposing small molecules, we had also postulated that DeepNEU had the potential to identify targets for vaccine development. In order to evaluate this possibility, we revisited the three anti-COVID-19 targets that had no small molecule candidates. These three genotypic options were orf1ab, orf7, and orf7/8. We were particularly interested in the polyprotein orf1ab which represents 70% of the SARS-CoV-2 genome and was the single most efficacious target we studied. The essential requirement for the identified factors to become potential vaccine targets is that they must be immunogenic. In fact, a recent computational analysis identified several SARS-CoV-2 antigenic proteins. While orf8a was the most antigenic of the proteins considered, it was rapidly degraded without its companion protein orf8b. ORF1ab was also determined to be antigenic 39 and polyclonal antibodies have successfully been raised against full length orf1ab recombinant protein in rabbits (Abnova, Catalog #: PAB11368). More recently, a multiepitope vaccine based on orf1ab sequences has been designed that is antigenic and capable of activating B cells and T cells. 40 We conclude that if antigenicity/ immunogenicity can be documented for a specific target, then

DeepNEU disease specific simulations may also be an important tool capable of identifying potential vaccine targets. our next project because of its high lethality to humans. It was discovered in Asia in 1999 and is associated with a 70% death rate in those infected. 4442 The NIPAH viral genome has been validated and there are currently no effective treatments. [42] [43] [44] Small outbreaks continue to occur in Southeast Asia and elsewhere. 30 Importantly, the WHO has gone so far as to identify NIPAH as a prototype for a future pandemic. 42, 43 It is our intension now to focus our efforts on creating disease simulations and identifying potentially effective therapies for all 10 of the WHO listed diseases. 39 

The coronavirus pandemic in five powerful charts

Use of induced pluripotent stem cells (iPSCs) and cerebral organoids in modeling the congenital infection and neuropathogenesis induced by Zika virus

Modeling viral infectious diseases and development of antiviral therapies using human induced pluripotent stem cell-derived systems

DeepNEU: artificially induced stem cell (aiPSC) and differentiated skeletal muscle cell (aiSkMC) simulations of infantile onset POMPE disease (IOPD) for potential biomarker identification and drug discovery

DeepNEU: cellular reprogramming comes of age-a machine learning platform with application to rare diseases research

Breadth of concomitant immune responses prior to patient recovery: a case report of nonsevere COVID-19

Bioengineered lungs generated from human iPSCs-derived epithelial cells on native extracellular matrix

Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools

Analysis of intraviral protein-protein interactions of the SARS coronavirus ORFeome

COVID-19: Attacks the 1-Beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism

Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic

Conversion of human and mouse fibroblasts into lung-like epithelial cells

Early lineage specification defines alveolar epithelial ontogeny in the murine lung

Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection

Lung organoids: current uses and future promise

The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China

The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds

Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research

Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways

Production of high purity alveolar-like cells from iPSCs through depletion of uncommitted cells after AFE induction

Interplay of deubiquitinating enzymes and cytokines

Generation of an alveolar epithelial type II cell line from induced pluripotent stem cells

Differentiation of human pluripotent stem cells into functional lung alveolar epithelial cells

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

WNT5a-ROR signaling is essential for alveologenesis

COVID-19 infection: origin, transmission, and characteristics of human coronaviruses

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

Predicting and designing therapeutics against the Nipah virus

Patient-specific induced pluripotent stem cells as a platform for disease modeling, drug discovery and precision personalized medicine

Drug screening for human genetic diseases using iPSC models

Open science meets stem cells: a new drug discovery approach for neurodegenerative disorders

Repurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface

Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Coronaviruses-drug discovery and therapeutic options

Compassionate use of Remdesivir for patients with severe Covid-19

Disease now and potential future pandemics. The World's Worst Problems

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

Deep learning vs. wise learning: a critical and challenging overview

The WHO R&D blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts

World Health Organization methodology to prioritize emerging infectious diseases in need of research and development

Introduction: Nipah virus-discovery and origin

Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing